Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jesús García-Donás Jiménez, MD
Spanish Oncology Genito-Urinary Group
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, A Coruña, Spain
- Hospital Universitario Fundación de Alcorcón
Alcorcón, Madrid, Spain
- Hospital del Mar
Barcelona, Spain
- Hospital Universitario Reina Sofía
Córdoba, Spain
- Hospital Universitario Central de Asturias
Oviedo, Spain
- Complejo Hospitalario de Navarra
Pamplona, Spain
- Fundación Instituto Valenciano de Oncología
Valencia, Spain
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2012
- Primary completion
- 31 Jul 2013
- Completion
- 30 Nov 2016
- Last update posted
- 25 Apr 2017
- Registered enrollment
- 17
- Registry id
- NCT01514526
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.